Abstract
Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have